Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ptc Therapeutics (PTCT) Other Operating Expenses (2017 - 2025)

Ptc Therapeutics has reported Other Operating Expenses over the past 11 years, most recently at $800000.0 for Q1 2025.

  • Quarterly results put Other Operating Expenses at $800000.0 for Q1 2025, up 700.0% from a year ago — trailing twelve months through Dec 2025 was $800000.0 (down 82.12% YoY), and the annual figure for FY2025 was $800000.0, down 82.12%.
  • Other Operating Expenses for Q1 2025 was $800000.0 at Ptc Therapeutics, down from $10.2 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for PTCT hit a ceiling of $128.9 million in Q2 2023 and a floor of -$10.8 million in Q3 2021.
  • Median Other Operating Expenses over the past 5 years was $100000.0 (2024), compared with a mean of $9.4 million.
  • Peak annual rise in Other Operating Expenses hit 11800.0% in 2022, while the deepest fall reached 152.07% in 2022.
  • Ptc Therapeutics' Other Operating Expenses stood at $12.1 million in 2021, then crashed by 152.07% to -$6.3 million in 2022, then skyrocketed by 142.86% to $2.7 million in 2023, then soared by 276.85% to $10.2 million in 2024, then tumbled by 92.14% to $800000.0 in 2025.
  • The last three reported values for Other Operating Expenses were $800000.0 (Q1 2025), $10.2 million (Q4 2024), and -$700000.0 (Q3 2024) per Business Quant data.